Overview of the drug development pipeline for atopic dermatitis
Atopic dermatitis (AD) is a chronic disease and is also known as eczema. It is a non-contagious inflammatory skin condition that is characterized by itchy dry skin, and on scratching, clear fluid may come out. AD is usually associated with elevated immunoglobulin E (IgE) levels. Researchers have come up with numerous drugs in various phases of drug development, targeting AD pathogenesis. Technavio’s market research analysts have predicted that with the introduction of molecules under development and molecules in discovery as some of the most promising approaches to treat multiple sclerosis, the global atopic dermatitis market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical and phase II developmental stages. For instance, sponsors such as AbbVie developed ABT-494 and Alchem Laboratories developed NanoDox, which are under phase II development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under discovery, phase I, and phase III stages. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I/II developmental stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of atopic dermatitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
Therapeutic assessment of the drug development pipeline for atopic dermatitis by route of administration
The topical route of administration (ROA) involves the administration of drug substances on the skin. It has been observed that the majority of total therapeutics are being developed for topical administration.
Therapeutic assessment of the drug development pipeline for atopic dermatitis by therapeutic modalities
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for atopic dermatitis are being developed as small molecules. Small molecules include lipids, monosaccharides, second messengers, as well as drugs and other xenobiotics organic compounds.
Key questions answered in the report include
What are the drug development molecules in the various development stages for atopic dermatitis?
What are the companies that are currently involved in the development of drug molecules for atopic dermatitis?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.